TY - JOUR T1 - Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems JO - Enfermedades Infecciosas y Microbiología Clínica (English Edition) T2 - AU - Cantón,Rafael AU - Oliver,Antonio AU - Alós,Juan Ignacio AU - de Benito,Natividad AU - Bou,Germán AU - Campos,José AU - Calvo,Jorge AU - Canut,Andrés AU - Castillo,Javier AU - Cercenado,Emilia AU - Domínguez,Maria Ángeles AU - Fernández-Cuenca,Felipe AU - Guinea,Jesús AU - Larrosa,Nieves AU - Liñares,Josefina AU - López-Cerero,Lorena AU - López-Navas,Antonio AU - Marco,Francesc AU - Mirelis,Beatriz AU - Moreno-Romo,Miguel Ángel AU - Morosini,María Isabel AU - Navarro,Ferran AU - Oteo,Jesús AU - Pascual,Álvaro AU - Pérez-Trallero,Emilio AU - Pérez-Vázquez,María AU - Soriano,Alex AU - Torres,Carmen AU - Vila,Jordi AU - Martínez-Martínez,Luis SN - 2529993X M3 - 10.1016/j.eimce.2019.01.011 DO - 10.1016/j.eimce.2019.01.011 UR - https://www.elsevier.es/en-revista-enfermedades-infecciosas-microbiologia-clinica-english-428-articulo-recommendations-spanish-antibiogram-committee-coesant--S2529993X20300599 AB - Automated antimicrobial susceptibility testing devices are widely implemented in clinical microbiology laboratories in Spain, mainly using EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. In 2007, a group of experts published recommendations for including antimicrobial agents and selecting concentrations in these systems. Under the patronage of the Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) and the Study Group on Mechanisms of Action and Resistance to Antimicrobial Agents (GEMARA) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and aligned with the Spanish National Plan against Antimicrobial Resistance (PRAN), a group of experts have updated this document. The main modifications from the previous version comprise the inclusion of new antimicrobial agents, adaptation of the ranges of concentrations to cover the EUCAST breakpoints and epidemiological cut-off values (ECOFFs), and the inference of new resistance mechanisms. This proposal should be considered by different manufacturers and users when designing new panels or cards. In addition, recommendations for selective reporting are also included. With this approach, the implementation of EUCAST breakpoints will be easier, increasing the quality of antimicrobial susceptibility testing data and their microbiological interpretation. It will also benefit epidemiological surveillance studies as well as the clinical use of antimicrobials aligned with antimicrobial stewardship programs. ER -